Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
Recent blog posts
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
|
|
October 20, 2022 · Clinical Team
When it comes to unused prescription medications, the Drug Enforcement Agency (DEA) encourages everyone to “Keep them safe. Clean them out. Take them back.” They enforce this motto by sponsoring National Prescription Drug Take Back Days. Read more... |
|
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
|
July 06, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more... |
|
|
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more... |
|
|
February 10, 2022 · Clinical Team
In October 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride (HCl) injection - ZIMHI™ (5 mg/0.5 mL) - to treat opioid analgesic overdose. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe that delivers 5 mg of naloxone HCl solution. Read more... |
|
|
December 09, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a new medication to prevent episodic migraine (fewer than fifteen headache days per month) on September 28, 2021. This approval allows AbbVie, Inc. to market Qulipta - a once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist - for migraine prevention. Qulipta is not indicated for the acute treatment of migraines like other oral CGRP receptor antagonists on the market, such as Ubrelvy™ (ubrogepant) and Nurtec® ODT (rimegepant). Qulipta is the second oral CGRP receptor antagonist to be approved for prevention of episodic migraine. Read more... |
Page 3 of 8
